Home/Pipeline/CV6-168

CV6-168

Oncology (Solid Tumors)

Phase 1aActive

Key Facts

Indication

Oncology (Solid Tumors)

Phase

Phase 1a

Status

Active

Company

CV6 Therapeutics

About CV6 Therapeutics

CV6 Therapeutics is a UK-based, private biotech founded in 2019, transitioning from an early-stage to a clinical-stage company. It is pioneering a novel approach targeting uracil-DNA metabolism to develop combination therapies that improve upon existing cornerstone treatments in large oncology and inflammatory disease markets. The company has initiated a Phase 1a trial for its lead oncology candidate and is preparing its inflammation candidate for the clinic, positioning itself in high-value therapeutic areas with significant unmet needs. Its strategy is built on a proprietary scientific platform with the potential for broad application across major disease areas.

View full company profile

Therapeutic Areas

Oncology Inflammatory Diseases

Other Oncology (Solid Tumors) Drugs

Drug	Company	Phase	Status
OATD-02	Molecure	Phase I	Active, recruiting
ANXV	Annexin Pharmaceuticals	Preclinical	Active
Athebody® DARPins for Targeted Radioligands (with POINT Biopharma)	Athebio	Pre-clinical	Active Partnership
AB821	Asher Biotherapeutics	Preclinical	Active
VEGF Kinoid	Neovacs	Preclinical	Inactive / Abandoned
Undisclosed Preclinical Pipeline	OncoResponse	Preclinical	Active
Undisclosed Platform Program	Da Zen Theranostics	Pre-clinical	Active
Compound42	Abbmira Therapeutics	Pre-clinical	Active
Clinical Decision Support Service	Curematch	Commercial	Active
Chemophototherapy (CPT)	POP Biotechnologies	Pre-clinical	Active
HRD Testing Solution	SeqOne Genomics	Commercial	Active
Platform Validation & Partnership Development	SingleCell Biotechnology	Pre-clinical	Active